Jian Jian Li

US Patent:

7741450, Jun 22, 2010

Filed:

Feb 8, 2007

Appl. No.:

11/672902

Inventors:

Philip M. Sass - Audubon PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Luigi Grasso - Bala Cynwyd PA, US
Jian Li - Fort Washington PA, US
Qimin Chao - Havertown PA, US
Eric Routhier - Glen Mills PA, US
Wolfgang Ebel - Philadelphia PA, US

Assignee:

Morphotek Inc. - Exton PA

International Classification:

C07K 16/24
C12N 5/12

US Classification:

53038823, 435326

Abstract:

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

US Patent:

8318168, Nov 27, 2012

Filed:

Apr 16, 2010

Appl. No.:

12/761464

Inventors:

Philip M. Sass - Audubon PA, US
Nicholas C. Nicolaides - Garnett Valley PA, US
Luigi Grasso - Bryn Mawr PA, US
Jian Li - Fort Washington PA, US
Qimin Chao - Havertown PA, US
Eric Routhier - Glen Mills PA, US
Wolfgang Ebel - Philadelphia PA, US

Assignee:

Morphotek, Inc. - Exton PA

International Classification:

A61K 39/395
C07K 16/22
C12P 21/08

US Classification:

4241411, 4241421, 4241451, 53038815, 53038823

Abstract:

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

US Patent:

8623364, Jan 7, 2014

Filed:

Oct 24, 2012

Appl. No.:

13/659165

Inventors:

Philip M. Sass - Audubon PA, US
Nicholas C. Nicolaides - Boothwyn PA, US
Luigi Grasso - Bala Cynwyd PA, US
Jian Li - Fort Washington PA, US
Qimin Chao - Havertown PA, US
Eric Routhier - Glen Mills PA, US
Wolfgang Ebel - Philadelphia PA, US

Assignee:

Morphotek, Inc. - Exton PA

International Classification:

A61K 39/395
C07K 16/00
C07K 16/22
C12P 21/08

US Classification:

4241411, 4241331, 4241391, 4241421, 4241451, 5303873, 5303879, 5303881, 53038815, 53038824

Abstract:

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

US Patent:

20040018195, Jan 29, 2004

Filed:

Mar 26, 2003

Appl. No.:

10/397786

Inventors:

Don Griswold - North Wales PA, US
Jian Li - Secane PA, US
Li Li - Downingtown PA, US

International Classification:

C07H021/04
A61K039/395
C12N005/06
C07K016/26
G01N033/543

US Classification:

424/145100, 530/388250, 435/336000, 435/069100, 536/023530, 436/518000

Abstract:

The present invention relates to at least one novel diabetes related human Ig derived protein or specified portion or variant, including isolated nucleic acids that encode at least one diabetes related Ig derived protein or specified portion or variant, diabetes related Ig derived protein or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

US Patent:

20050063944, Mar 24, 2005

Filed:

Sep 19, 2003

Appl. No.:

10/666490

Inventors:

Jian Li - Secane PA, US
Lamine Mbow - Malvern PA, US
Theresa Goletz - King of Prussia PA, US
David Peritt - Cynwyd PA, US

International Classification:

A61K038/19
A61K038/20

US Classification:

424085100, 424085200

Abstract:

The invention relates to the induction of responses relating to the maturation of dendritic cells, using IL-18 and IL-18 muteins, and compounds, compositions, methods of making and using thereof, including therapeutic methods and products.

US Patent:

20090048295, Feb 19, 2009

Filed:

Aug 12, 2008

Appl. No.:

12/190239

Inventors:

Joseph Kent Barbay - Flourtown PA, US
Wei He - Audubon PA, US
Yong Gong - Warrington PA, US
Jian Li - Lansdale PA, US
Jean Van Wauwe - Beerse, BE
Mieke Buntinx - Hasselt, BE

International Classification:

A61K 31/47
C07D 215/233
A61P 17/06
A61P 25/28

US Classification:

514312, 546153, 546171, 514311

Abstract:

Substituted 5,6,7,8-tetrahydroquinoline derivatives, which are C5receptor modulators, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, immune and inflammatory diseases and conditions, are disclosed.

US Patent:

20220281962, Sep 8, 2022

Filed:

Aug 12, 2020

Appl. No.:

17/634430

Inventors:

- New York NY, US
Weiqiang CHEN - Garden City NY, US
Jian Hua LI - New York NY, US
Kevin J. Tracey - Old Greenwich CT, US

International Classification:

C07K 16/18
A61P 29/02
A61P 19/02
A61P 39/00

Abstract:

Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.

US Patent:

20160333089, Nov 17, 2016

Filed:

Jul 18, 2016

Appl. No.:

15/212779

Inventors:

- Exton PA, US
Nicholas C. Nicolaides - Glen Mills PA, US
Luigi Grasso - Bryn Mawr PA, US
Wolfgang Ebel - Plymouth Meeting PA, US
Jian Li - Fort Washington PA, US
Qimin Chao - Havertown PA, US
Eric Routhier - Glen Mills PA, US

International Classification:

C07K 16/24

Abstract:

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.